New CEO for Merz Therapeutics: Stefan König
As of immediately, Stefan König will be responsible for Merz Therapeutics GmbH as CEO and Managing Director. As one of the businesses of Merz Group, Merz Therapeutics provides medical solutions for the treatment of serious health conditions such as neurological health impairments or diseases of the liver.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005731/en/
Stefan Koenig, CEO Merz Therapeutics (Photo: Business Wire)
Stefan König is an accomplished leader who has successfully worked in the pharmaceutical industry for his entire career, both at national and international market level. “Merz Therapeutics has had a successful development in last years. That is why we are very pleased to have won an exceptional executive with Stefan König who will continue to expand our business and take it to the next level. His profound expert knowledge in both clinical-stage drug development and commercialization as well as his experience in different global markets make him the ideal person to drive the future growth strategy of Merz Therapeutics,” says Phillip Burchard, CEO of the Merz Group and Chairman of the Merz Holding Board.
Until recently, Stefan König held the position of President and CEO of George Medicines, a London-based company focusing on the development of pharmaceuticals in an advanced clinical phase. George Medicines is a spin-off of the George Institute, one of the leading international health research institutes. Before this, Stefan König worked for many years at Takeda Pharmaceuticals, where he held various senior positions in global, regional and local functions. Among others, he was responsible for the global Inflammatory Bowel Disease franchise, after heading up a number of local and regional market organizations.
After a strategic reorganization three years ago, Merz Group created Merz Therapeutics as one of its three core businesses, with the goal for each of the individual businesses to have a better focus on specific customers and markets. Since then, Merz Therapeutics has developed favourably. The previous CEO and Managing Director of Merz Therapeutics, Stefan Brinkmann, is leaving Merz by best mutual agreement at the end of February after many years. With Stefan König’s appointment as of March 1, 2023, we will ensure a seamless transition.
About the Merz Group
The Merz Group is a global, diversified health care company based in Frankfurt, Germany. Family-owned for over 110 years, the company is distinguished by its commitment to innovation, a long-term perspective, and a focus on sustainable, profitable growth. The Merz Group includes the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate, and Merz Financial Investments. The company employs 3,730 people (as of financial year 21/22) in 28 countries worldwide. To learn more, please visit www.merz.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005731/en/
Contact information
Merz Pharma GmbH & Co. KGaA
Communications
Karolina Dzeko-Balke
Telephone number: +49 (0) 69 1503 2749
E-mail: karolina.dzeko-balke@merz.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom